60 Degrees Pharmaceuticals is a three-person Washington specialty house trying to convert an already-approved once-weekly malaria tablet into the first labeled therapy for babesiosis, a tick-borne red-cell infection that still has no Food and Drug Administration-approved treatment. The commercial product, ARAKODA, already sits in United States pharmacies and on travel-medicine telehealth platforms, but the residual claim is no longer about travel-clinic scripts. The residual claim is whether a randomized hospital study can produce an interim signal before cash runs out. Management's own liquidity discussion projects funding only through early October.
Product sales more than doubled in the June quarter, yet that print still covers only a sliver of the quarterly cost base. Gross profit barely moved because unit costs and yield losses at the sole active-ingredient vendor absorbed most of the volume gain. The first-half operating cash drain approached $5 million. The June cash balance sat just above $1 million. The July private placement added less than $1 million of net proceeds. The going-concern paragraph is not boilerplate here. It is the capital-structure fact that prices the equity.
The early-October Data Safety Monitoring Board look on the hospitalized study is the event that either funds a supplemental filing path or forces another dilutive round into an equity that already capitalizes near $4 million. Knight Therapeutics converted preferred stock in July and now holds roughly a fifth of the common. The question the next several weeks resolve is whether the babesiosis data arrive while there is still a public company left to own them.